GRAUS, F., D. ESCUDERO, L. OLEAGA, J. BRUNA, A. VILLAREJO-GALENDE, J. BALLABRIGA, M.I. BARCELO, F. GILO, S. POPKIROV, Pavel ŠTOURAČ a J. DALMAU. Syndrome and outcome of antibody-negative limbic encephalitis. European Journal of Neurology. Oxford: Rapid Science Ltd., 2018, roč. 25, č. 8, s. 1011-1016. ISSN 1351-5101. Dostupné z: https://dx.doi.org/10.1111/ene.13661.
Další formáty:   BibTeX LaTeX RIS
Základní údaje
Originální název Syndrome and outcome of antibody-negative limbic encephalitis
Autoři GRAUS, F. (724 Španělsko, garant), D. ESCUDERO (724 Španělsko), L. OLEAGA (724 Španělsko), J. BRUNA (724 Španělsko), A. VILLAREJO-GALENDE (724 Španělsko), J. BALLABRIGA (724 Španělsko), M.I. BARCELO (724 Španělsko), F. GILO (724 Španělsko), S. POPKIROV (276 Německo), Pavel ŠTOURAČ (203 Česká republika, domácí) a J. DALMAU (840 Spojené státy).
Vydání European Journal of Neurology, Oxford, Rapid Science Ltd. 2018, 1351-5101.
Další údaje
Originální jazyk angličtina
Typ výsledku Článek v odborném periodiku
Obor 30210 Clinical neurology
Stát vydavatele Spojené státy
Utajení není předmětem státního či obchodního tajemství
Impakt faktor Impact factor: 4.387
Kód RIV RIV/00216224:14110/18:00105960
Organizační jednotka Lékařská fakulta
Doi http://dx.doi.org/10.1111/ene.13661
UT WoS 000437832600011
Klíčová slova anglicky antibodies; autoimmune; limbic encephalitis; paraneoplastic
Štítky 14110221, rivok
Příznaky Mezinárodní význam, Recenzováno
Změnil Změnila: Soňa Böhmová, učo 232884. Změněno: 11. 2. 2019 14:01.
Anotace
Background and purposeThe aim was to report the clinical characteristics of 12 patients with limbic encephalitis (LE) who were antibody-negative after a comprehensive immunological study. MethodsThe clinical records of 163 patients with LE were reviewed. Immunohistochemistry on rat brain, cultured neurons and cell-based assays were used to identify neuronal autoantibodies. Patients were included if (i) there was adequate clinical, cerebrospinal fluid (CSF) and magnetic resonance imaging information to classify the syndrome as LE, (ii) magnetic resonance images were accessible for central review and (iii) serum and CSF were available and were confirmed negative for neuronal antibodies. ResultsTwelve (7%) of 163 LE patients [median age 62 years; range 40-79; 9 (75%) male] without neuronal autoantibodies were identified. The most frequent initial complaints were deficits in short-term memory leading to hospital admission in a few weeks (median time 2 weeks; range 0.5-12). In four patients the short-term memory dysfunction remained as an isolated symptom during the entire course of the disease. Seizures, drowsiness and psychiatric problems were unusual. Four patients had solid tumors (one lung, one esophagus, two metastatic cervical adenopathies of unknown primary tumor) and one chronic lymphocytic leukemia. CSF showed pleocytosis in seven (58%) with a median of 13 white blood cells/mm(3) (range 9-25). Immunotherapy included corticosteroids, intravenous immunoglobulins and combinations of both drugs or with rituximab. Clinical improvement occurred in six (54%) of 11 assessable patients. ConclusionsDespite the discovery of new antibodies, 7% of LE patients remain seronegative. Antibody-negative LE is more frequent in older males and usually develops with predominant or isolated short-term memory loss. Despite the absence of antibodies, patients may have an underlying cancer and respond to immunotherapy. Click for the corresponding questions to this CME article.
VytisknoutZobrazeno: 28. 7. 2024 23:24